|
|
|
European Biopharmaceutical Review
|
Initially, many smaller biologic drug substances − including recombinant proteins and peptides − were produced via microbial fermentation. However, with the advent of cell culture systems, interest shifted to mammalian systems to produce larger proteins and antibodies. Now, the introduction of smaller, complex next-generation molecules, such as bioconjugates, antibody fragments, and other scaffolds, are once again driving interest in fermentation as an effective manufacturing platform.
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
News and Press Releases |
 |
PharmaMarketing Summit returns 12-13 May in Boston, MA
We are thrilled to announce that the PHARMAMARKETING SUMMIT returns this May 12-13 in Boston, MA, USA!
The
summit brings leading pharmaceutical marketing executives and
innovative suppliers and service providers together at an exquisite
location the Encore Boston Harbor, Boston, MA, USA.
More info >> |
|
 |
White Papers |
 |
|
Streamlining patient recruitment using EHR data
The field of (bio)pharmaceutical research is booming. Increasingly more innovative therapeutics are being developed with the ability to drastically improve the quality of life of millions of patients around the world. Rigorously testing each of these candidate drugs for their safety and efficacy is an essential part of the development process. As the number of clinical trials steadily increases, the search for patients who present a specific medical profile and are willing to participate intensifies.
More info >> |
|
|
